A Dynamic Duo: Omnipod & Dexcom

Hosted by Nancy Hanna

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

Join us for an insightful journey into the world of diabetes management technology on this very special episode of Beyond the Bolus. Recorded live from the American Diabetes Association’s 83rd Scientific Sessions in San Diego, host Nancy Hanna is joined by Dexcom’s Cher Pastore in our very first simulcast.

To explore how Omnipod and Dexcom are influencing the dynamics of diabetes technology and reshaping patient outcomes for the better, they’re joined by Dr. Viral Shah - an endocrinologist whose research into these innovative therapies has touched and improved countless lives. During the episode, you'll discover how technological advancements are changing the game and reducing daily management burdens for people with diabetes. Hear invaluable insights from Dr. Shah on the importance of early adoption of tools such as CGM and the Omnipod 5, and how they can prove pivotal in managing diabetes and improving glycemic control. Dr. Shah examines the different barriers to technology adoption, and how fostering a pro-active conversation can help overcome them.

All this, plus a sneak peek into the future of diabetes tech.

Time stamps

2:25 – When is the best time to initiate technology for a person with diabetes on an intensive insulin regimen?
8:47 – Overcoming barriers to initiating technology
19:51 – Omnipod 5 is prescribed in the Pharmacy channel. Hear from Dr. Shah how that enables patients easier access to try it out and how it also makes it easier for the provider
22:06 – If a patient is new to technology, what does the journey look like?

 

See more episodes
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.

Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.